Patent and Publication
For the sustainable research and development, Meridigen has an intact blueprint in R&D, including comprehensive IP strategies in the stem cell industry. In concert with external collaborations and our own R&D team, we have patented in different countries for our stem cell technologies, including production processes, characterization platform and later drug assessments on the indication. These ensure the value of our products and our competitiveness worldwide.
We have established an appropriate IP management system that serves as a niche of our stem cells-based drugs. It ensures the competitiveness of our MSC-drugs before passing high-standard clinical trials and obtaining new drug approvals. With resources from Taiwanese Government, Meridigen has actively introduced the Taiwan Intellectual Property Management System (TIPS) framed by MOEIDB. The system reinforces the internal management on intellectual properties and external industrial competitiveness, enabling us open up a new perspective in the stem cell industry.
- Method of distinguishing mesenchymal stem cells
- Method of distinguishing mesenchymal stem cells and method of determining purity of mesenchymal stem cells.
1. Shih-Pei Shen, Wei-Ting Liu, Yun Lin, Yuan-Tsung Li, Chih-Hao Chang, Fung-Wei Chang, Le-Ming Wang, Sen-Wen Teng and Yogi Hsuan. EphA2 is a biomarker of hMSCs derived from human placenta and umbilical cord. Taiwanese Journal of Obstetrics &Gynecology 54 (2015) 749-756.
2. Hsiu-Chu Chou, Yuan-Tsung Li, Chung-Ming Chen. Human mesenchymal stem cells attenuate experimental bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Am J Transl Res. 2016; 8(2): 342–353.
3. Yen-Shun Chen, Yi-An Chen, Pei-Hsun Tsai, Chih-Ping Chen, ShengWen Shaw and Yogi Hsuan. Mesenchymal Stem Cell: Considerations for Manufacturing and Clinical Trials on Cell Therapy Product. Int J Stem Cell Res Ther. 2016. 3:029.
4. Hsiu-Chu Chou, Willie Lin and Chung-Ming Chen. Human mesenchymal stem cells attenuate pulmonary hypertension induced by prenatal lipopolysaccharide treatment in rats. Clin Exp Pharmacol Physiol. 2016. DOI: 10.1111/1440-1681.12604
5. Yogi Chang-Yo Hsuan, Cheng-Hsien Lin, Ching-Ping Chang and Mao-Tsun Lin. Mesenchymal stem cell-based treatments for stroke, neural trauma, and heat stroke. Brain and Behavior 2016 Aug 3;6(10): e00526.
6. Chung-Ming Chen, Hsiu-Chu Chou, Willie Lin and Chris Tseng. Surfactant effects on theviability and function of human mesenchymal stem cells: in vitro and in vivo assessment. Stem Cell Research & Therapy. (2017) 8:180.
7. Chung-Ming Chen, Willie Lin, Liang-Ti Huang and Hsiu-Chu Chou. Human mesenchymal stem cells ameliorate experimental pulmonary hypertension induced by maternal inflammation and neonatal hyperoxia in rats. Oncotarget. 2017 Jul 19. doi: 10.18632/oncotarget.19388.
8. Sen-Wen Teng, Yu Shu Lo, Wei-Ting Liu, Yogi Hsuan and Willie Lin. A genome-wide comparison of mesenchymal stem cells derived from human placenta and umbilical cord. Taiwanese Journal of Obstetrics and Gynecology. Taiwanese Journal of Obstetrics and Gynecology. 56 (2017) 664e671
9. Willie Lin, Yogi Chang-Yo Hsuan, Mao-Tsun Lin, Ting-Wei Kuo, Cheng-Hsien Lin, Yu-Chin Su, Ko-Chi Niu, Ching-Ping Chang and Hung-Jung Lin. Human umbilical cord mesenchymal stem cells preserve adult newborn neurons and reduce neurological injury after cerebral ischemia by reducing the number of hypertrophic microglia/ macrophages. Cell Transplantation. 2017, Vol. 26(11) 1798–1810.
10. Willie Lin, Yogi Chang-Yo Hsuan, Yu-Chin Su, Cheng-Hsien Lin, Mao-Tsun Lin, Zi-Hao Chen, Ching-Ping Chang, and Kao-Chang Lin. CD34-human placenta-derived mesenchymal stem cells protect against heat stroke mortality in rats.Oncotarget. December 15, 2017. DOI: 10.18632/oncotarget.23324
11. Hsu, Fei-Ting; Wei, Zung-Hang; Hsuan, Yogi Chang-Yo; Lin, Willie; Su, Yu-Chin; Liao, Chia-Hui; Hsieh, Chia-Ling. MRI tracking of polyethylene glycol–coated superparamagnetic iron oxide-labeled placenta-derived mesenchymal stem cells toward glioblastoma stem-like cells in a mouse model. Artificial Cells, Nanomedicine and Biotechnology. 2018 Sep 8:1-12
12. Yu-Chieh Wen, Mao-Kuang Du, Meng-Wei Li, Yogi Cheng-Yo Hsuan, Yu-Chin Su, Willie Lin. EphA2-positive human umbilical cord-derived mesenchymal stem cells exert anti-fibrosis and immunomodulatory activities via secretion of prostaglandin E2. Taiwanese Journal of Obstetrics and Gynecology. 2018 Oct;57(5):722-725
13. Dr Yu-Chin Su, Dr Willie Lin, Miss Yu-Chien Chen, Dr Yogi Cheng-Yo Hsuan, Professor Ching-Ping Chang, Dr Cheng-Hsien Lin, Dr Willy Chou. Modulation of parietal cytokine and chemokine gene profiles by mesenchymal stem cell as a basis for neurotrauma recovery. Journal of the Formosan Medical Association 2019 DOI: 10.1016/j.jfma.2019.01.008
14. Chih-Wei Chien, Yu-Shu Lo, Hsin-Yi Wu, Yogi Hsuan, Chia-Li Han, Yu-Ju Chen, Willie Lin. Transcriptomic and Proteomic Profiling of Human Mesenchymal Stem Cell Derived from Umbilical Cord in the Study of Preterm Birth. Proteomics-Clinical Applications (2019) (Submitted)
15. Hsiao-Chi Chuang, Xiao-Yue Chen, Yi-Ying Chen, Willie Lin, Chia-Wen Chien, Chien-Han Chen, Yu-Chieh Wen, Ta-Chih Hsiao. Effects of human umbilical cord-derived mesenchymal stem cells on the acute cigarette smoke-induced pulmonary inflammation model. Stem Cell Research (2019) (Submitted)